Form 4: Teva Director Tal Zvi Zaks Acquires Shares from RSU Vesting, Receives New Equity Grant

Teva Pharmaceutical Industries Ltd. Director Tal Zvi Zaks acquired 9,632 ordinary shares through the vesting of restricted share units and received a new grant of 14,492 restricted share units.

Summary

• Tal Zvi Zaks, a Director of Teva Pharmaceutical Industries Ltd., acquired 9,632 ordinary shares on June 6, 2025.
• This acquisition resulted from the vesting of 9,632 Restricted Share Units (RSUs) that were originally granted on June 6, 2024.
• Following this transaction, Mr. Zaks beneficially owns 58,772 ordinary shares of Teva.
• Additionally, Mr. Zaks was granted 14,492 new Restricted Share Units on June 5, 2025, which are scheduled to vest on June 5, 2026.

Sentiment

Score: 7

Explanation: The acquisition of shares through RSU vesting and the grant of new RSUs indicate ongoing equity compensation for a director, aligning their interests with the company's long-term performance. This is a routine and generally positive event for insider alignment.

Positives

• Director Tal Zvi Zaks acquired 9,632 ordinary shares, increasing his direct ownership in the company.
• The grant of 14,492 new Restricted Share Units aligns the director's incentives with long-term shareholder value.

Future Outlook

NA

Industry Context

This filing reflects routine equity compensation for a director in the pharmaceutical industry, aligning executive incentives with company performance through restricted share units.

Comparison to Industry Standards

• Equity compensation through Restricted Share Units (RSUs) is a common practice across the pharmaceutical and broader corporate sectors for aligning director and executive interests with long-term shareholder value.
• The specific number of shares and vesting schedules are typically determined by compensation committees based on company performance, individual contribution, and market benchmarks for similar roles in companies like Pfizer, Johnson & Johnson, or Novartis, though specific comparative data is not provided in this filing.

Corporate Governance

Related Party Transactions

• The acquisition of shares by Director Tal Zvi Zaks through the vesting of Restricted Share Units and the grant of new RSUs constitute related party transactions as they involve compensation between the company and a member of its board of directors.

Stakeholder Impact

• Shareholders: The vesting and grant of RSUs align the director's interests with shareholders, potentially encouraging long-term value creation.
• Management: Reinforces the compensation structure for directors.

Next Steps

• The 14,492 Restricted Share Units granted on June 5, 2025, are scheduled to vest on June 5, 2026.

Key Dates

Keywords

TEVA Pharmaceutical Industries, TEVA, Form 4, SEC filing, insider transaction, restricted share units, RSU vesting, director compensation, equity grant, beneficial ownership